Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:alsoKnownAs |
EORTC 26981/22981-MRC CE.3 trial
|
| gptkbp:clinicalTrialPhase |
NCT00006353
|
| gptkbp:conditionStudied |
gptkb:glioblastoma
|
| gptkbp:controlArm |
radiotherapy alone
|
| gptkbp:country |
multiple countries
|
| gptkbp:experimentalArm |
radiotherapy plus temozolomide
|
| gptkbp:foundIn |
temozolomide with radiotherapy improves survival in glioblastoma
|
| gptkbp:fullName |
European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial
|
| https://www.w3.org/2000/01/rdf-schema#label |
EORTC-NCIC trial
|
| gptkbp:impact |
established temozolomide as standard of care for glioblastoma
|
| gptkbp:numberOfPatients |
573
|
| gptkbp:principalInvestigator |
gptkb:Roger_Stupp
|
| gptkbp:publicationYear |
2005
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:sponsor |
gptkb:NCIC
gptkb:EORTC |
| gptkbp:startYear |
2000
|
| gptkbp:bfsParent |
gptkb:Stupp_protocol
|
| gptkbp:bfsLayer |
6
|